5 IPOs Scheduled for the Week of March 10

Francis Gaskins |

The full IPO calendar is available at IPOpremium.  Scheduled IPOs are ranked by IPO size.

(1) Based in Greenwich, CT, Diamond S Shipping Group (DSG) scheduled a $210 million IPO on the NYSE with a market capitalization of $710 million at a price range midpoint of $15 for Wednesday, March 12, 2014.

DSG provides seaborne transportation of refined petroleum and other products in the international shipping markets.  DSG is one of the largest owners and operators of medium range, or MR, product tankers in the world.

(2) Based in San Francisco, CA, Castlight Health (CSLT) scheduled a $111 million IPO on the NYSE with a market capitalization of $953 million at a price range midpoint of $10 for Friday, March 14, 2014.

CSLT markets and sells its Enterprise Healthcare Cloud offering to self-insured companies in a broad range of industries and governmental entities.



(3) Based in South San Francisco, CA, Achaogen (AKAO) scheduled a $65 million IPO on the Nasdaq with a market capitalization of $205 million at a price range midpoint of $13 for Wednesday, March 12, 2014.

AKAO is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections.

(4) Based in New York, NY, Dipexium Pharmaceuticals (DPRX) scheduled a $30 million IPO on the Nasdaq with a market capitalization of $100 million at a price range midpoint of $13 for Thursday, March 13, 2014.

DPRX is a late stage pharmaceutical company focused on the development and commercialization of Locilex™ (pexiganan acetate cream 1%), a novel, first-in-class, broad spectrum, topical antibiotic.

(5) Based in Tel Aviv, Israel, Galmed Pharmaceuticals (GLMD) scheduled a $31 million IPO on the Nasdaq with a market capitalization of $132 million at a price range midpoint of $13 for Thursday, March 13, 2014.

GLMD is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
DPRX Dipexium Pharmaceuticals Inc. n/a n/a n/a 0 Trade
CSLT Castlight Health Inc. Class B 4.35 0.20 4.82 2,131,656 Trade
GLMD Galmed Pharmaceuticals Ltd. 6.01 0.14 2.39 16,994 Trade
AKAO Achaogen Inc. 22.35 -0.14 -0.62 4,247,899 Trade
MWSNF Mawson Resources Ltd 0.25 0.00 0.00 0

Comments

Emerging Growth

Taranis Resources Inc.

Taranis Resources Inc is an exploration stage company. The Company along with its subsidiaries is engaged in the acquisition and exploration of mineral properties. Its projects include Thor Property in…

Private Markets

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…